House Renews Pediatric Exclusivity With Six-Month Incentive, More Mandatory Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
House-passed FDA reauthorization bill retains fundamental elements of exclusivity length, program sunset, but final legislation could require firms to develop more pediatric data.